Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? Acomparison of primary and adjuvant approaches
Nishant Patel1, Jason Woo1, Michael A. Liss1, Kerrin L. Palazzi1, J. Michael Randall2, Reza Mehrazin3, Ramzi Jabaji1, Hossein S. Mirheydar1, Kyle Gillis1, Hak J. Lee1, Anthony L. Patterson3, Christopher J. Kane1, Frederick Millard2, Ithaar H. Derweesh1
Canadian Journal of Urology, Vol.23, No.2, pp. 8227-8233, 2016
Abstract Introduction: To compare surgical complications and tyrosine kinase inhibitor (TKI)-toxicities in patients who underwent primary cytoreductive nephrectomy (CN) followed by adjuvant TKI therapy versus those who underwent neoadjuvant TKI therapy prior to planned CN for metastatic renal cell carcinoma (mRCC).
Materials and methods: Two-center retrospective analysis. Sixty-one mRCC patients underwent TKI therapy with sunitinib between July 2007 to January 2014. Patients were divided into three groups: primary CN followed by adjuvant TKI (n = 27, Group 1), neoadjuvant TKI prior to CN (n = 21, Group 2), and primary TKI alone (no surgery, n = 13, Group… More >